Question 1

What is Urgoskin?

Accepted Answer

Urgoskin is a Other.

Question 2

How often does Urgoskin appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 7 articles.

Question 3

When was Urgoskin first tracked by Ergen?

Accepted Answer

First tracked on May 19, 2026.

Question 4

When was Urgoskin last mentioned in news?

Accepted Answer

Last active on May 19, 2026.

Question 5

What is Urgoskin's current news sentiment?

Accepted Answer

Aggregate sentiment score: 20 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Urgoskin in global news coverage?

Accepted Answer

Attention score of 2, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Urgoskin?

Accepted Answer

OKYO_Pharma appoints Marta_Sacchetti to SAB (May 19, 2026, 7 articles).

Question 8

How did the "OKYO_Pharma appoints Marta_Sacchetti to SAB" event impact Urgoskin?

Accepted Answer

Urgoskin>>> is OKYO Pharma>>>'s lead investigational therapy for neuropathic corneal pain, which has received Fast Track designation from the United States — Food and Drug Administration>>> and showed positive results in Phase 2 trials.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.